A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen

Source

RELATED ARTICLESMORE FROM AUTHOR